Bone marrow stem cells injected for autism: first human safety test begins

NCT ID NCT07177677

Not yet recruiting Disease control Sponsor: Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial will test the safety of a single intravenous dose of stem cells derived from human bone marrow in 42 people aged 6 and older with autism spectrum disorder. Participants will receive one of three different doses. The study will monitor for side effects and also look for any signs of improvement in behavior and social skills, but it is too early to know if the treatment works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: human bone marrow mesenchymal stem cells (hBMMSC)
What this could lead to: If safe and effective, this could point toward a new way to ease core autism symptoms, though it is not a cure.
What could go wrong: This is a very early phase 1 trial with only 42 people, focused on safety. It is too soon to know if it works, and stem cell treatments carry risks like allergic reactions or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTISM SPECTRUM DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autism spectrum disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTISM SPECTRUM DISORDER

More trials for these conditions

Other studies related to the condition(s) this trial covers.